EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐Life Comparison of Antivirals for SARS‐CoV‐2 Omicron Infection in Patients With Hematologic Malignancies

Tommaso Francesco Aiello iD, Olivier Peyrony, Mariana Chumbita, Patricia Monzó, Carlos Lopera, Pedro Puerta-Alcalde, Laura Magnano, Francesc Fernández-Avilés, Genoveva Cuesta, Montse Tuset, Josep Mensa, Jordi Esteve und 3 weitere

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.13264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Tommaso Francesco Aiello und 14 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Hospital Clinic of Barcelona-IDIBAPS, Universitat de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: COVID-19, Hematologic Neoplasms, Lactams, Leucine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, FEDER, Agència de Gestión de Ayudas Universitarias y de Investigación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to describe a cohort of hematologic patients with COVID‐19 treated with antivirals early.

Methods

Non‐interventional chart review study. Comparison of baseline characteristics and outcomes in high‐risk hematologic patients treated with remdesivir between December 2021 and April 2022 versus those treated with nirmatrelvir/ritonavir between May and August 2022.

Results

Eighty‐three patients were analyzed. Forty‐two received remdesivir, and 41 nirmatrelvir/ritonavir. Patients with remdesivir were younger, vaccinated with lower number of doses, and received prior corticosteroids less frequently and sotrovimab, hyperimmune plasma and corticosteroids more often. Viral shedding median (IQR) duration was 18 (13–23) and 11 (8–21) days in the remdesivir and nirmatrelvir/ritonavir groups, respectively ( p = 0.004). Median (IQR) Ct values before treatment were similar in both groups. Within 5 days of treatment, median (IQR) Ct values were 26 (23–29) and 33 (30–37) in the remdesivir and nirmatrelvir/ritonavir groups, respectively ( p < 0.0001). All patients were hospitalized for remdesivir administration and only four (9.8%) in the nirmatrelvir/ritonavir group. The overall outcomes in this cohort of COVID‐19 patients with Omicron variant was good, as no patient needed oxygen or ICU admission. One patient in remdesivir group died from septic shock. No severe adverse event was recorded in both treatment groups.

Conclusions

Patients with hematologic malignancies and non‐severe COVID‐19 who received nirmatrelvir/ritonavir experienced faster decrease in viral load and shorter viral shedding. Furthermore, besides the advantage of oral administration, nirmatrelvir/ritonavir administration reduced the need of hospital admission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Hematologic NeoplasmsLactamsLeucineNitrilesProlineHumansRitonavirSARS-CoV-2Adrenal Cortex HormonesAntiviral AgentsCOVID-19 Drug Treatment

Stichwörter der Autor:innen

COVID-19Omicronnirmatrelvir/ritonaviroutcomephenotypes

Substanzen

nirmatrelvirRitonavirAdrenal Cortex HormonesAntiviral AgentsLactamsLeucineNitrilesProline

Autor:innen und Institutionen

  • Infectious Diseases Department, Hospital Clinic of Barcelona-IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
  • Emergency Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Department of Haematology, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Microbiology Department, Hospital Clinic, University of Barcelona, ISGLOBAL, Barcelona, Spain.
  • Department of Pharmacy, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.

ORCID-Profile: Tommaso Francesco Aiello

Förderung

  • Instituto de Salud Carlos III
  • FEDER
  • Agència de Gestión de Ayudas Universitarias y de Investigación
  • La Ligue Nationale contre le Cancer
  • La Direction de l'Assistance Publique - Hôpitaux de Paris
  • Federación Española de Enfermedades Raras
  • Agència de Gestió d'Ajuts Universitaris i de Recerca
  • Ligue Contre le Cancer

Zitieren

APA

Aiello, T. F., Peyrony, O., Chumbita, M., Monzó, P., Lopera, C., Puerta-Alcalde, P., Magnano, L., Fernández-Avilés, F., Cuesta, G., Tuset, M., Mensa, J., Esteve, J., Marcos, M. A., Soriano, A., & Garcia-Vidal, C. (2024). Real‐Life Comparison of Antivirals for SARS‐CoV‐2 Omicron Infection in Patients With Hematologic Malignancies. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13264

Vancouver

Aiello TF, Peyrony O, Chumbita M, Monzó P, Lopera C, Puerta-Alcalde P, et al. Real‐Life Comparison of Antivirals for SARS‐CoV‐2 Omicron Infection in Patients With Hematologic Malignancies. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13264

BibTeX
@article{Aiello2024,
  author = {Aiello, Tommaso Francesco and Peyrony, Olivier and Chumbita, Mariana and Monzó, Patricia and Lopera, Carlos and Puerta-Alcalde, Pedro and Magnano, Laura and Fernández-Avilés, Francesc and Cuesta, Genoveva and Tuset, Montse and Mensa, Josep and Esteve, Jordi and Marcos, Maria Angeles and Soriano, Alex and Garcia-Vidal, Carolina},
  title = {Real‐Life Comparison of Antivirals for SARS‐CoV‐2 Omicron Infection in Patients With Hematologic Malignancies},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.13264}
}
Kostenlos starten →